Mori K
Third Department of Internal Medicine, Fukushima Medical College, Japan.
Nihon Naibunpi Gakkai Zasshi. 1991 Jul 20;67(7):796-810. doi: 10.1507/endocrine1927.67.7_796.
The study was undertaken to clarify the role of atrial natriuretic polypeptide (ANP) in essential hypertension (EH). Plasma levels of alpha-human ANP (alpha hANP) were measured in 13 normal subjects, 25 patients with EH, 5 patients with primary aldosteronism (PA), 3 patients with renovascular hypertension (RVH) and 3 patients with pheochromocytoma (PC). Plasma level of alpha hANP (normal: 38.1 +/- 20.5pg/ml) was high in all hypertensive subjects. Synthetic alpha hANP was intravenously administrated to these subjects as follows: first a dose of 0.01 microgram/kg/min for 30 minutes, second a dose of 0.03 microgram/kg/min for 30 minutes, and then in normal subjects and EH 0.03 microgram/kg/min with a dose of 6.5 micrograms/kg/min of metoclopramide (MC) for 30 minutes. After the infusion of 0.01 microgram/kg/min alpha hANP, arterial blood pressure was significantly depressed in EH, RVH and PA, but not in PC. Marked diuretic and natriuretic responses were observed with increase in creatinine clearance and fractional sodium excretion in EH, RVH and PA, but not in PC. Sodium clearance/lithium clearance was slightly increased after infusion of 0.03 microgram/kg/min of alpha hANP in hypertensive subjects. Plasma renin activity did not change in low and normal renin EH and PA after infusion of either dose of alpha hANP, but was suppressed after 0.03 microgram/kg/min of alpha hANP in normal subjects and high renin EH, RVH and PC. Plasma aldosterone concentration was suppressed after either dose of alpha hANP in normal subjects and in EH, RVH and PC, but not in PA. Plasma cGMP concentration and urinary cGMP excretion were decreased after either dose of alpha hANP in both normal and hypertensive subjects. Furthermore, the decrease of PAC by alpha hANP was normalized by MC in normal subjects and EH. The rise in plasma cGMP by alpha hANP was suppressed by MC in both normal subjects and EH, but no changes were observed in arterial blood pressure and natriuretic response. These results suggest that alpha hANP secretion increases with elevation of blood pressure in EH, improving increase of circulatory blood volume, and alpha hANP may play a role in elevating blood pressure in EH. Moreover, it is considered that ANP increases sodium and water excretion through its effect on both renal glomeruli and distal tubules in EH. Hypotensive and natriuretic effects of ANP in EH may be concerned with dopaminergic activity which are probably related to the production of cGMP in the vascular wall and inhibition of the excretion of aldosterone in the adrenal cortex.
本研究旨在阐明心房利钠多肽(ANP)在原发性高血压(EH)中的作用。检测了13名正常受试者、25例EH患者、5例原发性醛固酮增多症(PA)患者、3例肾血管性高血压(RVH)患者和3例嗜铬细胞瘤(PC)患者的血浆α-人ANP(αhANP)水平。所有高血压受试者的血浆αhANP水平(正常:38.1±20.5pg/ml)均升高。对这些受试者静脉注射合成αhANP,具体如下:首先以0.01微克/千克/分钟的剂量注射30分钟,其次以0.03微克/千克/分钟的剂量注射30分钟,然后在正常受试者和EH患者中,以0.03微克/千克/分钟的剂量加用6.5微克/千克/分钟的甲氧氯普胺(MC)注射30分钟。静脉注射0.01微克/千克/分钟的αhANP后,EH、RVH和PA患者的动脉血压显著降低,但PC患者未降低。在EH、RVH和PA患者中观察到明显的利尿和排钠反应,同时肌酐清除率和钠排泄分数增加,但PC患者未出现。高血压受试者静脉注射0.03微克/千克/分钟的αhANP后,钠清除率/锂清除率略有增加。在低肾素和正常肾素的EH及PA患者中,注射任何一种剂量的αhANP后血浆肾素活性均无变化,但在正常受试者、高肾素EH、RVH和PC患者中,注射0.03微克/千克/分钟的αhANP后血浆肾素活性受到抑制。在正常受试者、EH、RVH和PC患者中,注射任何一种剂量的αhANP后血浆醛固酮浓度均受到抑制,但PA患者未受抑制。在正常和高血压受试者中,注射任何一种剂量的αhANP后血浆cGMP浓度和尿cGMP排泄均降低。此外,在正常受试者和EH患者中,αhANP引起的血浆醛固酮浓度降低可被MC恢复正常。在正常受试者和EH患者中,MC均抑制了αhANP引起的血浆cGMP升高,但动脉血压和排钠反应无变化。这些结果表明,EH患者中αhANP分泌随血压升高而增加,有助于改善循环血容量增加,且αhANP可能在EH患者血压升高中起作用。此外,认为ANP通过对EH患者肾肾小球和远端小管的作用增加钠和水排泄。ANP在EH患者中的降压和排钠作用可能与多巴胺能活性有关,这可能与血管壁中cGMP的产生以及肾上腺皮质中醛固酮排泄的抑制有关。